Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEVETEN vs BENICAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective angiotensin II receptor type 1 (AT1) antagonist, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, reducing blood pressure.
Hypertension,Treatment of hypertension (alone or in combination with other antihypertensive agents)
Treatment of hypertension in adults and children ≥6 years,Off-label: Diabetic nephropathy, heart failure
400-800 mg orally once daily; can be divided twice daily if needed for adequate blood pressure control.
Initial: 20 mg orally once daily; titrate to 40 mg once daily. Maximum 40 mg/day.
Terminal elimination half-life is approximately 7-8 hours in patients with normal renal function, supporting once-daily dosing.
Terminal elimination half-life is approximately 13–15 hours after multiple dosing, supporting once-daily dosing.
Primarily metabolized by glucuronidation (UGT1A3, UGT2B7); minimal CYP450 metabolism.
Prodrug olmesartan medoxomil is rapidly hydrolyzed to active olmesartan by esterases in gastrointestinal tract. Olmesartan is not metabolized by CYP450 enzymes and is excreted unchanged in bile and urine.
Renal (approximately 60% as unchanged drug) and biliary/fecal (approximately 40%).
Olmesartan is excreted primarily in feces (approximately 50–65%) via biliary elimination, with about 35–50% eliminated renally in urine as unchanged drug.
Approximately 99% bound to plasma proteins, primarily albumin.
Highly protein-bound (approximately 99%) to serum albumin.
Approximately 0.3 L/kg, indicating distribution mainly in extracellular fluid.
Volume of distribution is approximately 17 L (0.2–0.3 L/kg), indicating limited extravascular distribution.
Oral: approximately 15-20% due to extensive first-pass metabolism; absorption is not significantly affected by food.
Oral bioavailability is about 26–29% (absolute).
Cr Cl 30-59 m L/min: no adjustment; Cr Cl <30 m L/min: 200-400 mg once daily; hemodialysis: not studied, use with caution.
No adjustment for GFR ≥30 m L/min. For GFR <30 m L/min, initial dose 20 mg once daily; maximum 40 mg/day.
No adjustment required for mild to moderate impairment; not studied in severe impairment (Child-Pugh C).
No adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe impairment (Child-Pugh C).
Safety and efficacy not established in pediatric patients <18 years.
Safety and efficacy not established for pediatric patients <18 years.
No specific adjustment needed, but start at lower end of dosing range (400 mg once daily) due to potential renal impairment and increased sensitivity.
Initial 20 mg once daily; caution due to potential for reduced renal function. Monitor BP and electrolytes.
None
No FDA black box warning.
Avoid use in pregnancy (fetal toxicity/neonatal morbidity/mortality),Hypotension in volume-depleted patients (e.g., diuretic therapy, dialysis),Hyperkalemia in patients with renal impairment or potassium-sparing diuretics/supplements,Acute renal failure in patients with bilateral renal artery stenosis or solitary kidney,Monitor renal function and serum potassium periodically
May cause fetal harm if used during pregnancy,Avoid use in patients with severe renal impairment (Cr Cl <20 m L/min),Sprue-like enteropathy (severe chronic diarrhea with weight loss),Hypotension in volume-depleted patients,Hyperkalemia,Renal function deterioration in patients with renal artery stenosis
Concomitant use with aliskiren in patients with diabetes mellitus (type 2) or moderate to severe renal impairment (e GFR <60 m L/min/1.73 m²),Hypersensitivity to eprosartan or any component,Pregnancy (especially second and third trimesters)
Concomitant use with aliskiren in patients with diabetes mellitus,History of hypersensitivity to any component of the product
No specific food interactions. Avoid excessive potassium intake (e.g., potassium-rich foods like bananas, oranges, tomatoes, spinach) as TEVETEN may increase serum potassium. No restrictions with alcohol, but limit intake as it may lower blood pressure and increase side effects. Grapefruit juice has no known interaction.
No significant food interactions; may be taken with or without food. However, avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) if renal impairment is present or if taking potassium supplements.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure is associated with a low risk of congenital anomalies, but second- and third-trimester exposure is associated with oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal hypotension, anuria, and renal failure. TEVETEN (eprosartan mesylate) is an angiotensin II receptor blocker, and its use is contraindicated in pregnancy, especially during the second and third trimesters.
Pregnancy Category C (first trimester) and D (second and third trimesters). Exposure during the first trimester is associated with a potential risk of teratogenicity, though data are limited. Use in the second and third trimesters is known to cause fetal renal dysfunction, oligohydramnios, skull ossification deficits, and neonatal hypotension, hyperkalemia, and renal failure.
Eprosartan is excreted in rat milk at concentrations approximately 2.4 times higher than maternal plasma. No data exist on its excretion in human breast milk. Due to the potential for adverse effects in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. The M/P ratio in humans is unknown.
Minimal excretion into breast milk; M/P ratio is unknown. The American Academy of Pediatrics considers use compatible with breastfeeding, but caution is advised in preterm infants or those with renal impairment.
TEVETEN is contraindicated in pregnancy, and no dose adjustments are recommended because the drug should not be used. If pregnancy is detected, discontinue the drug as soon as possible. Pharmacokinetic changes in pregnancy, such as increased plasma volume, may alter the drug's effect, but use is not advised.
No dose adjustment typically required in pregnancy, but pharmacokinetic changes (increased volume of distribution, altered renal clearance) may necessitate careful blood pressure monitoring and dose titration. Avoid use during second and third trimesters if possible.
TEVETEN (eprosartan mesylate) is an angiotensin II receptor blocker (ARB) with a high affinity for the AT1 receptor. It has a dose-dependent antihypertensive effect. Avoid use in pregnancy; discontinue as soon as pregnancy is detected. Monitor renal function and serum potassium in patients with renal impairment, diabetes, or those on potassium-sparing diuretics. May cause angioedema, though rare. Use with caution in patients with unilateral or bilateral renal artery stenosis due to risk of acute renal failure.
BENICAR (olmesartan) is an angiotensin II receptor blocker (ARB) used primarily for hypertension. It demonstrates a dose-dependent antihypertensive effect with a once-daily dosing regimen. Monitor renal function and serum potassium, especially in patients with renal impairment or those on potassium-sparing diuretics. Avoid use in pregnancy (category D).
Take TEVETEN exactly as prescribed, usually once daily, with or without food.,Do not stop taking this medication without consulting your doctor, as it may worsen your condition.,Avoid becoming pregnant while on TEVETEN; use effective contraception and inform your doctor immediately if you think you are pregnant.,Report any signs of angioedema (swelling of face, lips, throat, difficulty breathing) or fainting to your doctor immediately.,Inform all healthcare providers that you are taking TEVETEN, especially before surgery or any procedure requiring anesthesia.,Stay hydrated, but do not use potassium supplements or salt substitutes containing potassium without medical advice.,Monitor your blood pressure regularly as directed and keep a log to share with your doctor.
Take exactly as prescribed, usually once daily with or without food.,It may take 2-4 weeks to see full blood pressure lowering effect.,Do not take if pregnant or planning pregnancy; use effective contraception.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium (muscle weakness, slow heartbeat) or low blood pressure (dizziness, fainting).,Stay hydrated but avoid excessive dehydration (e.g., from diarrhea or vomiting).,Do not abruptly stop this medication without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEVETEN vs BENICAR, answered by our medical review team.
TEVETEN is a Angiotensin II Receptor Blocker that works by Selective angiotensin II receptor type 1 (AT1) antagonist, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II.. BENICAR is a Angiotensin II Receptor Blocker that works by Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, reducing blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEVETEN and BENICAR depend on the specific clinical indication. These are both Angiotensin II Receptor Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEVETEN is: 400-800 mg orally once daily; can be divided twice daily if needed for adequate blood pressure control.. The standard adult dose of BENICAR is: Initial: 20 mg orally once daily; titrate to 40 mg once daily. Maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEVETEN and BENICAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEVETEN is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure is associated with a l. BENICAR is classified as Category C. Pregnancy Category C (first trimester) and D (second and third trimesters). Exposure during the first trimester is associated with a potential risk of teratogenicity, though data a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.